NCT06569056View on ClinicalTrials.gov

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

PHASE3RecruitingINTERVENTIONAL
Enrollment

578

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Interventions
DRUG

HRS-8427

Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

DRUG

Imipenem and Cilastatin Sodium

Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

DRUG

HRS-8427 placebo

Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

DRUG

Imipenem and Cilastatin Sodium placebo

Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

Trial Locations (1)

200040

RECRUITING

Shanghai Huashan Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY